Latest Administration News

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

Advance ZincTek posted an 11% rise in FY26 profit before tax to $2.247 million on 12.6% higher sales, driven by AI integration and US market strength. The company is set to enter residential battery manufacturing in FY27, leveraging its zinc oxide expertise.

Adslot Ltd swung to a $4.2 million profit in FY2026, buoyed by a $6 million non-cash gain from deconsolidating its troubled subsidiary. The company’s restructuring efforts trimmed costs by 28%, but revenue fell 10%.

Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.

Kina Securities lifted its half-year net profit by 4% to PGK 59.7 million, underpinned by a strong capital injection via Papua New Guinea’s inaugural listed corporate bond and a 13% higher interim dividend in local currency.

Island Pharmaceuticals has obtained regulatory rights to reference critical Marburg-Angola virus natural history data, clearing a significant FDA hurdle for its antiviral Galidesivir. This milestone accelerates the path toward pivotal animal studies and potential FDA approval under the Animal Rule.

CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.

Vection Technologies (ASX:VR1) achieved a major earnings inflection in FY26 with adjusted EBITDA soaring 596% to $3.8 million and generating positive operating cash flow for the first time, underpinned by dual commercial platforms scaling rapidly.

Critical Resources Limited has secured $1.6 million through a share placement to fund exploration across multiple jurisdictions and advance early-stage battery and thermal management technologies.

Genetic Technologies Limited slashed its net loss by nearly 88% in FY2025 following a Deed of Company Arrangement and exit from voluntary administration, pivoting to a corporate office model after selling its operating businesses.

Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.